Telenti A - Search Results

1

Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents.

Rotger M, Csajka C, Telenti A. Rotger M, et al. Among authors: telenti a. Curr HIV/AIDS Rep. 2006 Sep;3(3):118-25. doi: 10.1007/BF02696655. Curr HIV/AIDS Rep. 2006. PMID: 16970838 Review.

2

Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics.

Arab-Alameddine M, Décosterd LA, Buclin T, Telenti A, Csajka C. Arab-Alameddine M, et al. Among authors: telenti a. Expert Opin Drug Metab Toxicol. 2011;7(5):609-22. doi: 10.1517/17425255.2011.562891. Expert Opin Drug Metab Toxicol. 2011. PMID: 21500966 Review.

3

Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.

Csajka C, Marzolini C, Fattinger K, Décosterd LA, Fellay J, Telenti A, Biollaz J, Buclin T. Csajka C, et al. Among authors: telenti a. Clin Pharmacol Ther. 2003 Jan;73(1):20-30. doi: 10.1067/mcp.2003.22. Clin Pharmacol Ther. 2003. PMID: 12545140

4

Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus.

Csajka C, Marzolini C, Fattinger K, Décosterd LA, Telenti A, Biollaz J, Buclin T. Csajka C, et al. Among authors: telenti a. Antimicrob Agents Chemother. 2004 Sep;48(9):3226-32. doi: 10.1128/AAC.48.9.3226-3232.2004. Antimicrob Agents Chemother. 2004. PMID: 15328077 Free PMC article. Clinical Trial.

5

Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders.

Tarr PE, Taffé P, Bleiber G, Furrer H, Rotger M, Martinez R, Hirschel B, Battegay M, Weber R, Vernazza P, Bernasconi E, Darioli R, Rickenbach M, Ledergerber B, Telenti A; Swiss HIV Cohort Study. Tarr PE, et al. Among authors: telenti a. J Infect Dis. 2005 May 1;191(9):1419-26. doi: 10.1086/429295. Epub 2005 Mar 22. J Infect Dis. 2005. PMID: 15809899 Free article.

6

Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients.

Rotger M, Colombo S, Furrer H, Bleiber G, Buclin T, Lee BL, Keiser O, Biollaz J, Décosterd L, Telenti A; Swiss HIV Cohort Study. Rotger M, et al. Among authors: telenti a. Pharmacogenet Genomics. 2005 Jan;15(1):1-5. doi: 10.1097/01213011-200501000-00001. Pharmacogenet Genomics. 2005. PMID: 15864119

7

Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia.

Rotger M, Taffe P, Bleiber G, Gunthard HF, Furrer H, Vernazza P, Drechsler H, Bernasconi E, Rickenbach M, Telenti A; Swiss HIV Cohort Study. Rotger M, et al. Among authors: telenti a. J Infect Dis. 2005 Oct 15;192(8):1381-6. doi: 10.1086/466531. Epub 2005 Sep 9. J Infect Dis. 2005. PMID: 16170755 Free article.

8

Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection.

Colombo S, Buclin T, Cavassini M, Décosterd LA, Telenti A, Biollaz J, Csajka C. Colombo S, et al. Among authors: telenti a. Antimicrob Agents Chemother. 2006 Nov;50(11):3801-8. doi: 10.1128/AAC.00098-06. Epub 2006 Aug 28. Antimicrob Agents Chemother. 2006. PMID: 16940065 Free PMC article.

9

Does tenofovir influence efavirenz pharmacokinetics?

Rotger M, Colombo S, Furrer H, Décosterd L, Buclin T, Telenti A. Rotger M, et al. Among authors: telenti a. Antivir Ther. 2007;12(1):115-8. Antivir Ther. 2007. PMID: 17503755

10

ADME pathway approach for pharmacogenetic studies of anti-HIV therapy.

Lubomirov R, Csajka C, Telenti A. Lubomirov R, et al. Among authors: telenti a. Pharmacogenomics. 2007 Jun;8(6):623-33. doi: 10.2217/14622416.8.6.623. Pharmacogenomics. 2007. PMID: 17559351 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

593 results

Search Page